LU91571I2 - Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine - Google Patents

Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine

Info

Publication number
LU91571I2
LU91571I2 LU91571C LU91571C LU91571I2 LU 91571 I2 LU91571 I2 LU 91571I2 LU 91571 C LU91571 C LU 91571C LU 91571 C LU91571 C LU 91571C LU 91571 I2 LU91571 I2 LU 91571I2
Authority
LU
Luxembourg
Prior art keywords
alkyl
aryl
alkoxy
substd
halo
Prior art date
Application number
LU91571C
Other languages
English (en)
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91571(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of LU91571I2 publication Critical patent/LU91571I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Phenolic Resins Or Amino Resins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU91571C 1991-02-21 2009-05-11 Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine LU91571I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP9658891 1991-04-26
JP13488991 1991-06-06
JP16713891 1991-07-08
JP17397291 1991-07-15
JP18484191 1991-07-24

Publications (1)

Publication Number Publication Date
LU91571I2 true LU91571I2 (fr) 2009-07-13

Family

ID=27549327

Family Applications (4)

Application Number Title Priority Date Filing Date
LU91056C LU91056I2 (fr) 1991-02-21 2004-01-26 Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique.
LU91330C LU91330I2 (fr) 1991-02-21 2007-04-02 Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus)
LU91571C LU91571I2 (fr) 1991-02-21 2009-05-11 Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine
LU91847C LU91847I2 (fr) 1991-02-21 2011-07-26 Combinaison de olmesartan medoxomil, optionnellement sous forme d'un sel pharmaceutiquement acceptable, et amlodipine besylate et hydrochlorothiazide

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LU91056C LU91056I2 (fr) 1991-02-21 2004-01-26 Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique.
LU91330C LU91330I2 (fr) 1991-02-21 2007-04-02 Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus)

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU91847C LU91847I2 (fr) 1991-02-21 2011-07-26 Combinaison de olmesartan medoxomil, optionnellement sous forme d'un sel pharmaceutiquement acceptable, et amlodipine besylate et hydrochlorothiazide

Country Status (23)

Country Link
EP (2) EP0545912B1 (fr)
JP (1) JPH07121918B2 (fr)
KR (1) KR0128289B1 (fr)
CN (3) CN1045770C (fr)
AT (2) ATE200778T1 (fr)
CA (2) CA2229000C (fr)
CZ (1) CZ289194B6 (fr)
DE (6) DE69231798T3 (fr)
DK (2) DK0545912T3 (fr)
ES (2) ES2156866T3 (fr)
FI (2) FI112942B3 (fr)
GR (2) GR3035909T3 (fr)
HK (2) HK1011361A1 (fr)
HU (3) HU223338B1 (fr)
IE (1) IE920540A1 (fr)
IL (3) IL114996A (fr)
IS (1) IS1756B (fr)
LU (4) LU91056I2 (fr)
NL (3) NL300133I2 (fr)
NO (6) NO304516B3 (fr)
NZ (1) NZ241681A (fr)
PT (2) PT545912E (fr)
RU (1) RU2128173C1 (fr)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
ATE199548T1 (de) * 1992-06-02 2001-03-15 Sankyo Co 4-carboxyimidazolderivate als angiotensin-ii- antagonisten und ihre therapeutische verwendung
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
HUT74734A (en) * 1994-03-16 1997-02-28 Sankyo Co Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
DK0930076T3 (da) 1996-07-15 2005-01-31 Sankyo Co Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom
AU5576498A (en) * 1997-02-05 1998-08-26 Sankyo Company Limited Prophylactic or therapeutic agent for diabetic complication
CA2375287A1 (fr) * 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Methode de production de derives d'imidazole
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
EP1314425A4 (fr) * 2000-08-30 2004-06-02 Sankyo Co Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1336407B1 (fr) * 2000-11-21 2006-05-03 Sankyo Company, Limited Composition comprenant un antagonist du recepteur de l'angiotensine ii et un diuretique et leur utilisation pour le traitement de l'hypertension
WO2003020315A1 (fr) * 2001-08-28 2003-03-13 Sankyo Company, Limited Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
EP3045174A1 (fr) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Médicament pour la prévention et le traitement de l'artériosclérose et de l'hypertension
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
BRPI0409293A (pt) * 2003-04-15 2006-04-11 Sankyo Co medicamento para a prevenção ou tratamento de doenças angiogênicas intraoculares
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
WO2005051298A2 (fr) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
WO2005077941A2 (fr) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Polymorphes de candesartan cilexetil
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
BRPI0508880A (pt) 2004-03-17 2007-09-04 Novartis Ag uso de compostos orgánicos
CN1976926A (zh) * 2004-09-02 2007-06-06 特瓦制药工业有限公司 奥美沙坦酯的制备
PL1799199T3 (pl) 2004-10-08 2012-09-28 Novartis Ag Zastosowanie inhibitorów reniny do zapobiegania lub leczenia dysfunkcji rozkurczowej albo rozkurczowej niewydolności serca
NZ555325A (en) 2004-10-27 2009-07-31 Daiichi Sankyo Co Ltd Benzene compound having 2 or more substituents
US20060148870A1 (en) * 2004-12-30 2006-07-06 Lilach Hedvati Process for preparing olmesartan medoxomil AT pH higher than 2.5
CA2592160A1 (fr) * 2005-01-03 2006-07-13 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil a teneur reduite en impuretes
US20090082411A1 (en) * 2005-04-22 2009-03-26 Ryuuichi Morishita Pharmaceutical for prevention or treatment of bone metabolic disease
CA2616466A1 (fr) * 2005-07-29 2007-02-15 Krka Procede de preparation d'olmesartane medoxomil
EP1816131A1 (fr) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Procédé pour la préparation du olmesartan medoxomil
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (fr) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Formes polymorphes du Olmesartan Medoxomil
EP1990052B1 (fr) 2006-02-27 2012-05-16 Takeda Pharmaceutical Company Limited Emballage pharmaceutique comprenant du 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate de (5-methyl-2-oxo-1,3-dioxol-4-yl)methyle ou du 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate de (5-methyl-2-oxo-1,3-dioxol-4-yl)methyle et un agent deshydratant
EP1891952B1 (fr) 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Composition pharmaceutique d'olmésartan médoxomil
US8048904B2 (en) * 2006-06-19 2011-11-01 Matrix Laboratories Ltd. Process for the preparation of olmesartan medoxomil
KR101126383B1 (ko) 2007-02-07 2012-04-12 교와 핫꼬 기린 가부시키가이샤 3환계 화합물
EP2117540A1 (fr) 2007-03-01 2009-11-18 Probiodrug AG Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
EP2141160A4 (fr) * 2007-03-23 2011-06-29 Daiichi Sankyo Co Ltd Cristal moulu d'olmésartan médoxomil
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
ES2446296T3 (es) * 2007-06-22 2014-03-07 Daiichi Sankyo Company, Limited Agente medicinal para el tratamiento de trastornos de la circulación cerebral o del flujo sanguíneo cerebral inducidos por beta amiloide
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
JP5415416B2 (ja) * 2008-06-09 2014-02-12 第一三共株式会社 １−ビフェニルメチルイミダゾール化合物の製造方法
WO2010009319A2 (fr) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP3081213B1 (fr) 2008-08-06 2020-04-01 Kyowa Kirin Co., Ltd. Composé tricyclique
WO2010054515A1 (fr) 2008-11-17 2010-05-20 上海医药工业研究院 Procédé de préparation de 4-(1-hydroxy-1-méthyléthyl)-2-propyl-imidazole-5-carboxylates
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CN102414200B (zh) 2009-04-28 2014-12-17 第一三共株式会社 奥美沙坦酯的制备方法
EP2426127B1 (fr) 2009-04-28 2019-09-04 Daiichi Sankyo Company, Limited Nouveaux cristaux solvates
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
CA2785920A1 (fr) 2010-01-05 2011-07-14 Ratiopharm Gmbh Forme posologique orale solide contenant de l'olmesartan medoxomil
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (fr) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations de l'olmesartane
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2013018899A1 (fr) 2011-08-03 2013-02-07 協和発酵キリン株式会社 Dérivé de dibenzooxépine
WO2013090196A1 (fr) 2011-12-15 2013-06-20 Takeda Pharmaceuticals U.S.A., Inc. Combinaisons d'azilsartan et de chlorthalidone pour le traitement de patients hypertendus noires
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN104583185A (zh) 2012-08-31 2015-04-29 株式会社Api 联芳基化合物的制造方法
IN2015DN02241A (fr) 2012-09-26 2015-08-21 Api Corp
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
ES2847904T3 (es) 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
CN108778334A (zh) 2016-03-24 2018-11-09 第三共株式会社 用于治疗肾脏疾病的药物
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (fr) * 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
EP0400835A1 (fr) 1989-05-15 1990-12-05 Merck & Co. Inc. Benzimidazoles substitués comme antagoniste d'angiotensine II
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
EP0515548A4 (en) * 1990-02-13 1993-03-10 Merck & Co. Inc. Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
GR3035906T3 (en) 2001-08-31
HK1011361A1 (en) 1999-07-09
NO954507L (no) 1992-08-24
HU223667B1 (hu) 2004-11-29
PT503785E (pt) 2001-08-30
GR3035909T3 (en) 2001-08-31
IL101034A (en) 1996-10-16
NO2011013I1 (no) 2011-08-22
FI920749A0 (fi) 1992-02-20
IE970752A1 (en) 2000-02-23
IL101034A0 (en) 1992-11-15
DE69231798D1 (de) 2001-05-31
CN1189490A (zh) 1998-08-05
FI112942B3 (fi) 2012-03-13
CZ51692A3 (en) 1993-03-17
NO2006012I1 (no) 2006-10-30
ES2157895T7 (es) 2012-06-14
EP0545912A2 (fr) 1993-06-09
HU211934A9 (en) 1996-01-29
HUT60475A (en) 1992-09-28
NL300375I1 (nl) 2009-04-01
NO920688L (no) 1992-08-24
LU91330I2 (fr) 2007-06-04
CZ289194B6 (cs) 2001-11-14
HU9200578D0 (en) 1992-05-28
EP0545912B1 (fr) 2001-04-25
NO2009019I1 (no) 2009-09-21
FI920749A (fi) 1992-08-22
NO304517B1 (no) 1999-01-04
IS1756B (is) 2000-12-28
PT545912E (pt) 2001-08-30
AU1112592A (en) 1992-08-27
CN1188645A (zh) 1998-07-29
CA2229000C (fr) 2002-04-09
JPH07121918B2 (ja) 1995-12-25
FI955248A0 (fi) 1995-11-02
CN1101384C (zh) 2003-02-12
FI112942B (fi) 2004-02-13
NO2003009I2 (en) 2007-12-11
NL300227I1 (nl) 2006-06-01
DE122011000011I1 (de) 2011-06-16
FI955248A (fi) 1995-11-02
HK1011969A1 (en) 1999-07-23
NO304516B1 (no) 1999-01-04
IL114996A (en) 1997-07-13
EP0503785A1 (fr) 1992-09-16
JPH0578328A (ja) 1993-03-30
CA2229000A1 (fr) 1992-08-22
LU91056I2 (fr) 2004-10-19
HU9601179D0 (en) 1996-07-29
DE10299043I1 (de) 2003-03-27
NL300133I2 (nl) 2004-03-01
CN1045770C (zh) 1999-10-20
NZ241681A (en) 1993-07-27
DE69231801D1 (de) 2001-05-31
RU95101430A (ru) 1997-02-20
RU2128173C1 (ru) 1999-03-27
CN1065063A (zh) 1992-10-07
LU91847I2 (fr) 2011-09-26
KR0128289B1 (ko) 1998-04-02
DE122005000051I1 (de) 2006-01-26
CA2061607A1 (fr) 1992-08-22
FI112941B (fi) 2004-02-13
IE920540A1 (en) 1992-08-26
DK0503785T3 (da) 2001-06-18
EP0545912A3 (fr) 1993-06-16
CA2061607C (fr) 1999-01-19
NO954507D0 (no) 1995-11-09
EP0503785B3 (fr) 2012-02-29
ES2157895T3 (es) 2001-09-01
CN1121859C (zh) 2003-09-24
DE69231801T2 (de) 2001-12-06
IL114996A0 (en) 1995-12-08
ES2156866T3 (es) 2001-08-01
KR920016429A (ko) 1992-09-24
DE122009000024I1 (de) 2009-09-17
IS3819A (is) 1992-08-22
DE10299043I2 (de) 2003-08-07
NL300133I1 (nl) 2003-10-01
NO920688D0 (no) 1992-02-21
ATE200777T1 (de) 2001-05-15
ATE200778T1 (de) 2001-05-15
NO304516B3 (no) 2012-06-11
EP0503785B1 (fr) 2001-04-25
HU223338B1 (hu) 2004-06-28
DE69231798T3 (de) 2012-07-12
AU647887B2 (en) 1994-03-31
DK0545912T3 (da) 2001-06-18
DE69231798T2 (de) 2001-12-06

Similar Documents

Publication Publication Date Title
LU91571I2 (fr) Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine
RS51436B (en) DERIVATIVES TRIAZOLIL TROPANA KAO MODULATORS CCR5